• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Maternal Health Inequities: Improving Access to Postpartum Depression Treatment

Commentary
Podcast

Douglas Weber, MD, explains how zuranolone has changed the landscape for postpartum depression treatment, addressing a gap in care within maternal health.

Zuranolone (Zurzuvae; Sage Therapeutics/Biogen), the first oral medication approved by the FDA for postpartum depression (PPD), became available at the end of last year, offering physicians and patients an effective and more convenient treatment option for managing PPD.

In this episode of Managed Care Cast, hosted by the Center on Health Equity & Access, Douglas Weber, MD, OB-GYN at MomDoc, explained why this therapy has impacted maternal and postpartum care. Previously, treatment for PPD was limited to intravenous (IV) administration of brexanolone (Zulresso) or commonly prescribed antidepressant medications which are not necessarily designed to address the hormonal components of PPD.

iTunes
TuneIn
Stitcher
Spotify

Related Videos
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Pierluigi Porcu, MD
Kimberly Westrich, MA, chief strategy officer, NPC
Image credit: Medical technology and futuristic concept. Doctor hologram modern virtual screen interface | SOMKID - stock.adobe.com
Erin Weber, MS
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Marla Black Morgan, MD, Phoebe Neurology Associates
Elizabeth Grush, MBA
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.